{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:10:33Z","timestamp":1761185433527,"version":"build-2065373602"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"21","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this review is to guide practitioners through the certainty, and uncertainty, that surrounds optimal management of antithrombotic therapies in patients with lower-extremity peripheral arterial disease. It also provides practitioners with a framework from which to apply these therapies safely and effectively to optimize patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Peripheral arterial disease is an underdiagnosed and undertreated disease entity. Chronic antithrombotic therapies play a pivotal role in the prevention of thrombotic events in patients with lower-extremity peripheral arterial disease. Whether antiplatelet therapy, oral anticoagulation, or a combination of antiplatelet and anticoagulant therapies is best suited to prevent major cardiovascular and limb events in this patient population has been a long-standing clinical question. There is a great deal of variability in real-world practice as to which agents and dose intensities are used chronically for this purpose. Recent major publications exploring the use of \u201cdual-pathway inhibition\u201d have helped clarify best antithrombotic practices in patients with symptomatic peripheral arterial disease, and these have had a major impact on recently updated guidelines in the US, Europe, and Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pharmacists play an important role in reevaluating antithrombotic regimens for all patients with peripheral arterial disease, recognizing that recent landmark publications have led to substantial changes to international guidelines. Dual-pathway inhibition with combined low-dose rivaroxaban and low-dose aspirin therapy should be considered in all patients with symptomatic peripheral arterial disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf157","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:56:13Z","timestamp":1750233373000},"page":"e868-e877","source":"Crossref","is-referenced-by-count":0,"title":["Selecting oral antithrombotic therapies in peripheral arterial disease: A guide for practitioners"],"prefix":"10.1093","volume":"82","author":[{"given":"Jeremy W","family":"Vandiver","sequence":"first","affiliation":[{"name":"University of Wyoming School of Pharmacy , Laramie, WY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"8","key":"2025102219521142700_zxaf157-B1","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"8","key":"2025102219521142700_zxaf157-B2","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics 2021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"issue":"19","key":"2025102219521142700_zxaf157-B3","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","article-title":"Three-year follow-up and event rates in the international Reduction of Atherothrombosis for Continued Health Registry","volume":"30","author":"Alberts","year":"2009","journal-title":"Eur Heart J"},{"issue":"18","key":"2025102219521142700_zxaf157-B4","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2017.02.064","article-title":"Underuse of prevention and lifestyle counseling in patients with peripheral artery disease","volume":"69","author":"Berger","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"2025102219521142700_zxaf157-B5","doi-asserted-by":"publisher","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"issue":"36","key":"2025102219521142700_zxaf157-B6","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"issue":"5","key":"2025102219521142700_zxaf157-B7","first-page":"560","article-title":"Canadian Cardiovascular Society 2022 guidelines for peripheral arterial disease","volume":"38","author":"Abramson","year":"2022","journal-title":"Can J Cardiol"},{"issue":"1","key":"2025102219521142700_zxaf157-B8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamacardio.2020.4390","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"21","key":"2025102219521142700_zxaf157-B9","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2025102219521142700_zxaf157-B10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.cjca.2020.06.008","article-title":"A national Canadian survey of antithrombotic therapy after urgent and emergent limb revascularization","volume":"37","author":"McClure","year":"2021","journal-title":"Can J Cardiol"},{"issue":"4","key":"2025102219521142700_zxaf157-B11","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jvs.2014.12.050","article-title":"Role of high shear rate in thrombosis","volume":"61","author":"Casa","year":"2015","journal-title":"J Vasc Surg"},{"issue":"14","key":"2025102219521142700_zxaf157-B12","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"2025102219521142700_zxaf157-B13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7326\/M15-2112","article-title":"Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force","volume":"164","author":"Whitlock","year":"2016","journal-title":"Ann Intern Med"},{"issue":"8","key":"2025102219521142700_zxaf157-B14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelii","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2025102219521142700_zxaf157-B15","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","article-title":"Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal\/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs\/alcohol concomitantly) score","volume":"57","author":"Lip","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2025102219521142700_zxaf157-B16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11239-018-1635-0","article-title":"Combining oral anticoagulation and antiplatelet therapies: appropriate patient selection","volume":"45","author":"Vandiver","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"2025102219521142700_zxaf157-B17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ejvs.2021.12.019","article-title":"The OAC3-PAD risk score predicts major bleeding events one year after hospitalisation for peripheral artery disease","volume":"63","author":"Behrendt","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2025102219521142700_zxaf157-B18","doi-asserted-by":"publisher","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"issue":"9","key":"2025102219521142700_zxaf157-B19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes","year":"2010","journal-title":"JAMA"},{"issue":"18","key":"2025102219521142700_zxaf157-B20","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","article-title":"Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials","volume":"301","author":"Berger","year":"2009","journal-title":"JAMA"},{"issue":"12","key":"2025102219521142700_zxaf157-B21","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s40265-022-01756-6","article-title":"Antithrombotic therapy for symptomatic peripheral arterial disease: a systematic review and network meta-analysis","volume":"82","author":"Willems","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"2025102219521142700_zxaf157-B22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2796.2006.01763.x","volume":"261","author":"Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial","year":"2007","journal-title":"J Intern Med"},{"issue":"9038","key":"2025102219521142700_zxaf157-B23","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/s0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"issue":"1","key":"2025102219521142700_zxaf157-B24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2025102219521142700_zxaf157-B25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534.30","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoubi","year":"2009","journal-title":"Eur Heart J"},{"issue":"23","key":"2025102219521142700_zxaf157-B26","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2025102219521142700_zxaf157-B27","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapy\u2014the MIRROR study: a randomised and double-blinded clinical trial","volume":"22","author":"Tepe","year":"2012","journal-title":"Eur Radiol"},{"issue":"23","key":"2025102219521142700_zxaf157-B28","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.jcin.2019.08.006","article-title":"Optimal strategy for antiplatelet therapy after endovascular revascularization for lower extremity peripheral artery disease","volume":"12","author":"Cho","year":"2019","journal-title":"JACC Cardiovasc Intervent"},{"issue":"4","key":"2025102219521142700_zxaf157-B29","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"issue":"2","key":"2025102219521142700_zxaf157-B30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejvs.2019.09.006","article-title":"European Society for Vascular Surgery (ESVS) 2020 clinical practice guidelines on the management of acute limb ischaemia","volume":"59","author":"Bjorck","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"6","key":"2025102219521142700_zxaf157-B31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1258\/rsmvasc.12.6.362","article-title":"Hemorrhagic complications during long-term postoperative warfarin administration in patients undergoing lower extremity arterial bypass surgery","volume":"12","author":"Johnson","year":"2004","journal-title":"Vascular"},{"issue":"9201","key":"2025102219521142700_zxaf157-B32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","volume":"355","author":"Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"2025102219521142700_zxaf157-B33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa065959","volume":"357","author":"Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","year":"2007","journal-title":"N Engl J Med"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf157\/63513426\/zxaf157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/21\/e868\/63513426\/zxaf157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/21\/e868\/63513426\/zxaf157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:52:20Z","timestamp":1761177140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/21\/e868\/8166555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":33,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,6,18]]},"published-print":{"date-parts":[[2025,10,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf157","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"type":"print","value":"1079-2082"},{"type":"electronic","value":"1535-2900"}],"subject":[],"published-other":{"date-parts":[[2025,11,1]]},"published":{"date-parts":[[2025,6,18]]}}}